Galmed Pharma (GLMD) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
- Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
